Holen Sie sich die Stockscreener-App
3.08
0.33%
0.01
Handel nachbörslich:
3.23
0.15
+4.87%
Schlusskurs vom Vortag:
$3.07
Offen:
$3.05
24-Stunden-Volumen:
118.02K
Relative Volume:
2.06
Marktkapitalisierung:
$26.08M
Einnahmen:
$10.16M
Nettoeinkommen (Verlust:
$-47.57M
KGV:
-0.3301
EPS:
-9.33
Netto-Cashflow:
$-42.73M
1W Leistung:
-13.73%
1M Leistung:
-16.76%
6M Leistung:
-61.31%
1J Leistung:
-74.61%
1-Tages-Spanne:
$3.05
$3.26
1-Wochen-Bereich:
$3.05
$3.79
52-Wochen-Spanne:
$3.05
$17.49
Curis Inc Stock (CRIS) Company Profile
Firmenname
Curis Inc
Sektor
Branche
Telefon
617-503-6500
Adresse
128 SPRING STREET, LEXINGTON, MA
Vergleichen Sie CRIS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRIS
Curis Inc
|
3.08 | 26.08M | 10.16M | -47.57M | -42.73M | -8.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Curis Inc Stock (CRIS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-17 | Eingeleitet | Truist | Buy |
| 2022-04-04 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-10-13 | Eingeleitet | Raymond James | Outperform |
| 2021-03-25 | Eingeleitet | B. Riley Securities | Buy |
| 2020-07-29 | Eingeleitet | Laidlaw | Buy |
| 2020-07-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-10-24 | Eingeleitet | Guggenheim | Buy |
| 2016-03-02 | Eingeleitet | Sun Trust Rbsn Humphrey | Buy |
| 2015-11-09 | Bestätigt | ROTH Capital | Buy |
| 2015-08-11 | Eingeleitet | FBR Capital | Outperform |
| 2015-01-22 | Bestätigt | Oppenheimer | Outperform |
| 2015-01-21 | Bestätigt | ROTH Capital | Buy |
| 2014-05-09 | Bestätigt | Oppenheimer | Outperform |
| 2013-10-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2013-09-30 | Eingeleitet | Chardan Capital Markets | Buy |
| 2012-11-14 | Eingeleitet | Stifel Nicolaus | Hold |
| 2012-01-31 | Bestätigt | Brean Murray | Buy |
| 2012-01-31 | Bestätigt | Summer Street Research | Buy |
| 2011-12-09 | Eingeleitet | Oppenheimer | Outperform |
| 2011-10-06 | Eingeleitet | Summer Street Research | Buy |
| 2011-09-22 | Eingeleitet | MLV Capital | Buy |
| 2011-03-21 | Bestätigt | Brean Murray | Buy |
| 2010-02-26 | Bestätigt | Roth Capital | Buy |
| 2010-01-07 | Eingeleitet | Roth Capital | Buy |
Alle ansehen
Curis Inc Aktie (CRIS) Neueste Nachrichten
Curis Inc (CRIS) Stock Surges Amid Positive Analyst Ratings - GuruFocus.com
Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024 - The Eastern Progress Online
Curis stock plunges to 52-week low, hits $3.5 amid downturn By Investing.com - Investing.com South Africa
Curis stock plunges to 52-week low, hits $3.5 amid downturn - Investing.com Canada
Curis reports promising AML study results By Investing.com - Investing.com Canada
Curis, Inc. Announces Additional Data from Take Aim Leukemia Study - Marketscreener.com
Curis reports promising AML study results - Investing.com India
Curis Announces Additional Data from TakeAim Leukemia Study - PR Newswire
Curis (NASDAQ:CRIS) Shares Down 2.3% – Time to Sell? - Defense World
Curis (CRIS) Total Inventories : $0.00 Mil (As of Sep. 2024) - GuruFocus.com
Curis to Present at Upcoming Healthcare Conferences in September - The Eastern Progress Online
Curis Inc (CRIS) Stock Surges 5.46% Amid Positive Analyst Ratings - GuruFocus.com
Curis Announces $12.1 Million Registered Direct and Concurrent P - GuruFocus.com
Curis to Report Third Quarter 2024 Financial and Operating Resul - GuruFocus.com
Curis Provides Third Quarter 2024 Business Update - GuruFocus.com
Curis: Q3 Earnings Snapshot - Marketscreener.com
Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Curis’ (CRIS) Buy Rating Reiterated at HC Wainwright - Defense World
Curis Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Curis, Inc. (NASDAQ:CRIS) Q3 2024 Earnings Call Transcript - Insider Monkey
Curis Inc (CRIS) Q3 2024 Earnings Call Highlights: Navigating Fi - GuruFocus.com
Curis Inc (CRIS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ... - Yahoo Finance
Earnings call: Curis Reports Progress in Clinical Studies and Financials - Investing.com India
Curis Inc. Reports Positive Q3 2024 Earnings - TipRanks
Curis reports progress in clinical trials By Investing.com - Investing.com Australia
Curis Inc (CRIS) Quarterly 10-Q Report - Quartzy
Curis Inc (CRIS) Q3 2024 Earnings: Revenue Surpasses Estimates a - GuruFocus.com
Curis reports progress in clinical trials - Investing.com
Curis Reports Improved Q3 Loss, Achieves Strong Clinical Response in Cancer Study | CRIS Stock News - StockTitan
Curis, Inc.'s (NASDAQ:CRIS) 26% Dip In Price Shows Sentiment Is Matching Revenues - Simply Wall St
Curis (FRA:CUS0) Total Inventories : €0.00 Mil (As of Jun. 2024) - GuruFocus.com
Kingdon Capital Management Reduces Stake in Curis Inc - GuruFocus.com
Curis stock touches 52-week low at $3.95 amid market challenges - Investing.com India
Curis Inc (CRIS) Q3 2024: Everything You Need to Know Ahead of E - GuruFocus.com
Curis (CRIS) Set to Announce Quarterly Earnings on Thursday - Defense World
Curis (CRIS) to Report Q3 2024 Earnings: Key Updates on IRAK4 Inhibitor Progress | CRIS Stock News - StockTitan
Curis Inc. (CRIS) Stock Surges 5.08% Amid Strong Biotech Sector Performance - GuruFocus.com
Curis stock hits 52-week low at $4.05 amid market challenges - Investing.com Canada
Curis shares remain Buy-rated, H.C. Wainwright lowers target after cash infusion extends runway - Investing.com Canada
Finanzdaten der Curis Inc-Aktie (CRIS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):